FIELD: medicine.
SUBSTANCE: invention refers to pharmacology. A solid pharmaceutical dispersion contains bazedoxifene acetate dispersed in a dispersant, and said dispersant contains polyvinylpyrrolidone, poloxamer, polyethylene glycol, or a mixture or copolymer of said substances. The invention refers also to the compositions containing said dispersion, to methods for making the solid pharmaceutical dispersion containing bazedoxifene acetate and the composition and a dosage form containing the solid pharmaceutical dispersion containing bazedoxifene acetate for treatment of a disease or a syndrome associated with oestrogen hunger or excess, a disease or a disorder associated with proliferation or pathological development of endometrial tissues, cholesterol reduction, bone loss inhibition and breast cancer treatment. Besides the invention covers the methods of treating mammals suffering a disease or a syndrome associated with oestrogen hunger or excess, or a disease or a disorder associated with proliferation or pathological development of endometrial tissues, or cholesterol reduction in a mammal, bone loss inhibition in a mammal or breast cancer treatment in a mammal, treatment of one or more vasomotor disorders in postmenopausal women, including the introduction of therapeutically effective amounts of the solid pharmaceutical dispersion, and also to the application of the solid pharmaceutical dispersion containing bazedoxifene acetate for preparing a drug for treatment of a disease or a syndrome associated with oestrogen hunger or excess, a disorder associated with proliferation or pathological development of endometrial tissues, cholesterol reduction, bone loss inhibition and breast cancer treatment.
EFFECT: invention provides higher clinical effectiveness.
38 cl, 6 tbl, 2 dwg, 4 ex
Title | Year | Author | Number |
---|---|---|---|
BAZEDOXIFENE TREATMENT SCHEDULE | 2003 |
|
RU2355397C2 |
PHARMACEUTICAL COMPOSITIONS CONTAINING CONJUGATED ESTROGENS AND BAZEDOXIFENE | 2006 |
|
RU2395286C2 |
SOLID DISPERSIONS, CONTAINING KINASE INHIBITORS | 2011 |
|
RU2566716C2 |
SOLID DISPERSION | 2012 |
|
RU2648448C2 |
COMPOSITIONS CONTAINING BAZEDOXIFENE ACETATE | 2006 |
|
RU2417084C2 |
SOLID DISPERSIONS | 2016 |
|
RU2694832C2 |
(-)-CIS-6(S)-PHENYL-5(R)-[4-(2-PYRROLIDINE-1-YLETHOXY)PHENYL]- -5,6,7,8-TETRAHYDRONAPHTHALINE-2-OL D-TARTRATE, METHOD OF ITS SYNTHESIS, METHOD OF PROPHYLAXIS OF STATES INFLUENCING WITH TO EFFECT OF ESTROGEN AGONISTS, PHARMACEUTICAL COMPOSITION | 1996 |
|
RU2162465C2 |
TREATMENT OF BRAIN CANCER | 2013 |
|
RU2672575C2 |
NAPHTHYL DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND INTERMEDIATE SUBSTANCES | 1996 |
|
RU2167849C2 |
TRANSDERMAL DELIVERY OF LAZOPHOXIPHEN | 2001 |
|
RU2328276C2 |
Authors
Dates
2010-09-27—Published
2005-04-07—Filed